Omeros Corporation (OMER) Receives Consensus Rating of “Buy” from Brokerages
Omeros Corporation (NASDAQ:OMER) has earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the company. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $39.50.
A number of analysts have commented on the company. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price objective on shares of Omeros Corporation in a report on Wednesday, August 10th. Maxim Group decreased their price objective on Omeros Corporation from $30.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. Wedbush reissued an “outperform” rating and set a $56.00 price objective (down from $62.00) on shares of Omeros Corporation in a report on Thursday, August 11th. Zacks Investment Research lowered Omeros Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. Finally, FBR & Co reissued an “outperform” rating and set a $38.00 price objective on shares of Omeros Corporation in a report on Wednesday, June 29th.
In other Omeros Corporation news, VP Marcia S. Kelbon sold 16,000 shares of the stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total transaction of $174,560.00. Following the completion of the transaction, the vice president now directly owns 179,597 shares of the company’s stock, valued at $1,959,403.27. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Marcia S. Kelbon sold 15,900 shares of the stock in a transaction on Monday, August 15th. The shares were sold at an average price of $11.56, for a total value of $183,804.00. Following the transaction, the vice president now directly owns 179,497 shares of the company’s stock, valued at $2,074,985.32. The disclosure for this sale can be found here. 13.60% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in OMER. Sheaff Brock Investment Advisors LLC purchased a new position in shares of Omeros Corporation during the second quarter valued at $105,000. Bourgeon Capital Management LLC purchased a new position in shares of Omeros Corporation during the second quarter valued at $158,000. BlackRock Advisors LLC raised its position in shares of Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 173 shares during the period. Mesirow Financial Investment Management Equity Management purchased a new position in shares of Omeros Corporation during the second quarter valued at $244,000. Finally, Gradient Investments LLC raised its position in shares of Omeros Corporation by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 814 shares during the period. 48.04% of the stock is owned by institutional investors and hedge funds.
Omeros Corporation (NASDAQ:OMER) traded up 2.4509% during mid-day trading on Monday, reaching $7.5199. The company had a trading volume of 3,543,098 shares. Omeros Corporation has a one year low of $7.26 and a one year high of $16.80. The company’s 50-day moving average is $10.60 and its 200-day moving average is $11.73. The stock’s market capitalization is $295.48 million.
Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.18. The company had revenue of $10 million for the quarter, compared to the consensus estimate of $9.80 million. The business’s revenue for the quarter was up 212.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.44) earnings per share. Equities research analysts anticipate that Omeros Corporation will post ($1.55) earnings per share for the current year.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.